国产紫杉醇联合卡铂治疗晚期非小细胞肺癌23例分析  

Combined Chemotherapy of Paclitaxel and Carboplatin in the Treatment of 23 Patients with Advanced Non-Small Cell Lung Cancer

作　　者：于杰[1] 衣喜梅 张楠[1] 

机构地区：[1]青岛市第三人民医院,山东青岛266000 [2]青岛双桃医院

出　　处：《潍坊医学院学报》2006年第1期32-33,共2页Acta Academiae Medicinae Weifang

摘　　要：目的观察国产紫杉醇联合卡铂方案治疗晚期非小细胞肺癌(NSCLC)的疗效和毒副反应。方法选取初治晚期非小细胞肺癌23例,采用紫杉醇、卡铂方案联合化疗,按WHO疗效及毒副反应评价标准,完成2个周期以上治疗的患者进行临床疗效及不良反应评估。结果可评价患者23例,有效率为39.1%,随诊20例中位生存期为8.9个月,1年生存率为40%(8/20)。全组毒性反应主要为血液学毒性,其中Ⅲ-Ⅳ期白细胞降低发生率为39.1%(9/23),血小板下降发生率为8.7%(2/23),血红蛋白下降发生率为4.3%(1/23)。结论紫杉醇联合卡铂治疗晚期非小细胞肺癌较好疗效。不良反应可耐受,安全性高,可在临床推广应用。Objective To observe the efficacy and toxicity of combined chemotherapy of domestic paclitxel and carboplation in the treatment of advanced non-small cell lung cancer （NSCLC）. Methods A total of 23 initially treated patients with advanced NSCLC were enrolled in this study and treated by combined chemotherapy of domestis paclitaxel and carboplatin. The clinical efficacy and toxicity were evaluated after two cycles of chemotherapy according to WHO standard. Results Twenty-three patients could be evaluted. The response rate was 39.1%（9/23）. Twenty patients were followed up. The 1-year survival was 40% （8/20） and thd median survival duration was 8.9 months. The main toxicity were hematoloical toxicity （Grade Ⅲ-Ⅳ leukopenia 39.1% （9/23）, decreased plateletcell count 8.7% （2/23）, thrombocytopenia 4.3% （1/23）. Conclusion Combined chemotherapy of paclitaxel and carboplatin is a good regimen for advanced non-small cell lung cancer with good efficacy and well-tolerated side effects.

关 键 词：紫杉醇 卡铂 非小细胞肺癌 联合化疗 

分 类 号：R730.53[医药卫生—肿瘤]